Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 chronology.

C J Hawkey1

  • 1Wolfson Digestive Diseases Centre, University of Nottingham, University Hospital, Nottingham, NG7 2UH, UK. cj.hawkey@nottingham.ac.uk

Gut
|October 18, 2005
PubMed
Summary
This summary is machine-generated.

Selective cyclooxygenase (COX)-2 inhibitors, intended for pain relief, are controversial due to increased heart attack risks. Understanding historical drug development lessons is crucial for present-day medical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eradication of <i>Helicobacter pylori</i> for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: the HEAT RCT.

Health technology assessment (Winchester, England)·2025
Same author

Welcome to Frontline Gastroenterology.

Frontline gastroenterology·2017
Same author

What you need to know when you prescribe a proton pump inhibitor.

Frontline gastroenterology·2017
Same author

A drunk and disorderly country: a nationwide cross-sectional survey of alcohol use and misuse in Great Britain.

Frontline gastroenterology·2017
Same author

Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art Treatment.

Digestive diseases (Basel, Switzerland)·2017
Same author

Stem cells as treatment in inflammatory bowel disease.

Digestive diseases (Basel, Switzerland)·2013
Same journal

CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease.

Gut·2026
Same journal

<i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials.

Gut·2026
Same journal

Correction: Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.

Gut·2026
Same journal

Correction: Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.

Gut·2026
Same journal

Cancer risk in autoimmune gastritis: perspectives from a Chinese cohort.

Gut·2026
Same journal

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.

Gut·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Safety

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin have a long history of pain management.
  • Selective cyclooxygenase (COX)-2 inhibitors were developed as potentially safer alternatives to traditional NSAIDs.
  • The development of pain relief medications is driven by significant clinical demand.

Observation:

  • Selective COX-2 inhibitors, while effective for pain, have been linked to an elevated risk of myocardial infarction.
  • The mechanism of action involves the inhibition of cyclooxygenase enzymes.
  • Adverse effects, though sometimes unanticipated, can be predicted based on drug class properties.

Findings:

  • The use of selective COX-2 inhibitors presents a complex risk-benefit profile.

Related Experiment Videos

  • Historical precedents demonstrate recurring patterns of efficacy and adverse events in drug classes.
  • Understanding the evolution of NSAIDs and their successors is key to evaluating current drug safety.

    • Implications:

    • Lessons from the history of NSAIDs and COX-2 inhibitors can inform the development and regulation of future pain medications.
    • A historical perspective is essential for navigating the controversies surrounding selective COX-2 inhibitors.
    • Applying past learnings can mitigate future risks associated with widely used therapeutic agents.